Shield Therapeutics (STU:1JS) Cash-to-Debt : 2.36 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shield Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2023 was 2.36.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Shield Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Shield Therapeutics's Cash-to-Debt or its related term are showing as below:

STU:1JS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: No Debt Max: No Debt
Current: 2.36

During the past 9 years, Shield Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was No Debt.

STU:1JS's Cash-to-Debt is ranked better than
62.71% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs STU:1JS: 2.36

Shield Therapeutics Cash-to-Debt Historical Data

The historical data trend for Shield Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Shield Therapeutics Cash-to-Debt Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

66.32

203.54

104.77

77.50

0.46

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial													No Debt	77.50	No Debt	0.46	2.36

Competitive Comparison of Shield Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Cash-to-Debt falls into.

Shield Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Shield Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.244	/	(0.102	+	6.908)
	=	0.46

Shield Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.843	/	(0.078	+	6.649)
	=	2.36

Shield Therapeutics (STU:1JS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Shield Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (STU:1JS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (STU:1JS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SHIEF:USA STX:UK 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.

Shield Therapeutics (STU:1JS) Headlines

No Headlines